COL4A1 and COL4A2-Related Disorders: Research and Treatment Development

COL4A1 and COL4A2 provide instructions for two chains of type IV collagen. Together, these help form basement membranes: thin supporting layers around blood vessels and other tissues. Disease-causing variants can affect this support network, with consequences for vessel integrity and organ function. COL4A1 disease overview

Gould syndrome is used by patient organisations and some clinical resources as an umbrella name for the spectrum associated with disease-causing COL4A1 or COL4A2 variants. Clinical reports may instead describe a specific presentation, such as porencephaly, small-vessel brain disease or HANAC syndrome. The name does not mean all presentations, variants or treatment needs are identical. Gould Syndrome Foundation Clinical recommendations

Many COL4A1/COL4A2 disorders are autosomal dominant: a disease-causing variant in one copy of a gene can be sufficient. In this situation, each child of a person carrying the variant has a 50% chance of inheriting it. Variants can also arise for the first time in a child. Rarer inheritance patterns have been reported, so counselling should use the specific genetic result.

The same family can include people with very different features. A genetic result helps explain a cause but does not, by itself, predict an individual's course. Inheritance and clinical spectrum

Possible brain features include bleeding, stroke, seizures, developmental difficulties and porencephaly, where a fluid-filled cavity forms after early brain injury. Some people are diagnosed in childhood; others first come to attention in adulthood. Eye abnormalities, kidney involvement and muscle symptoms can also occur, with patterns that differ between people. Clinical features

Diagnosis combines the clinical picture, brain imaging and genetic testing. A specialist may arrange eye, kidney or other assessments depending on the findings. A pathogenic or likely pathogenic variant supports diagnosis; a variant of uncertain significance requires further interpretation and should not be treated as proof on its own. Diagnosis and assessment

Management is tailored to the organs affected. It may include treatment of seizures, rehabilitation, developmental support and care for eye or kidney complications. Blood-pressure management and avoiding smoking are relevant to vascular health.

Bleeding risk, activities that could cause head injury, pregnancy and medicines that affect clotting deserve individual discussion with the clinical team. There is no single management plan for every COL4A1/COL4A2 presentation. The 2025 clinical recommendations support coordinated care across appropriate specialties. Management overview Updated clinical recommendations

Published evidence: Our collagen gene-editing review describes approaches across different collagen disorders, including CRISPR-based methods. Results in another collagen disease cannot be assumed to apply to COL4A1/COL4A2-related brain disease. Read the published review

Our research: Led by Dr Klaudia Kocsy, this project investigates disease-relevant models, drug repurposing and gene-targeted correction strategies. The team's public project contributions are described below. These are experimental approaches, not treatments currently offered through CSVD Therapeutics.

Future aims: Establish whether candidates improve meaningful disease readouts, reach the relevant cells and meet safety requirements. Drug repurposing still requires evidence for the new indication; existing use for another condition does not establish benefit here. Explore our therapeutic development roadmap and Sheffield clinical research.

The broader collagen research space includes Ehlers–Danlos syndromes, a distinct group of connective-tissue disorders. They are not another name for COL4A1/COL4A2 disease, and research results should be interpreted for the specific condition. Collagen disorders and research scope